Head to Head Contrast: Vir Biotechnology (NASDAQ:VIR) vs. Crescent Biopharma (NASDAQ:CBIO)

Vir Biotechnology (NASDAQ:VIR) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

Vir Biotechnology has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500.

Profitability

This table compares Vir Biotechnology and Crescent Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Crescent Biopharma	N/A	-101.50%	-86.86%

Analyst Ratings

This is a breakdown of current ratings for Vir Biotechnology and Crescent Biopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1	0	6	1	2.88
Crescent Biopharma	1	1	2	2	2.83

Vir Biotechnology presently has a consensus price target of $21.57, indicating a potential upside of 103.50%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 75.25%. Given Vir Biotechnology’s stronger consensus rating and higher probable upside, equities analysts plainly believe Vir Biotechnology is more favorable than Crescent Biopharma.

Institutional & Insider Ownership

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Vir Biotechnology and Crescent Biopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56 million	26.16	-$437.99 million	($1.86)	-5.70
Crescent Biopharma	$10.84 million	57.87	-$153.94 million	($6.72)	-2.51

Crescent Biopharma has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Vir Biotechnology beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks.

About Vir Biotechnology

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.